Syros Pharmaceuticals (SYRS) - Price-to-Projected Revenue Ratio
Syros Pharmaceuticals (SYRS) is developing advanced gene expression modulation methods to combat hematologic malignancies, mitigating risks through research diversification. The GURU.Markets platform reports the firm's forward P/S, where the 8.20 mark characterizes this parameter. Despite fierce competition with pharma behemoths, Syros Pharmaceuticals is actively expanding its drug portfolio, planning the launch of a therapy for acute myeloid leukemia by 2026.
SYRS (Syros Pharmaceuticals, Inc): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization indicators:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital Syros Pharmaceuticals|SYRS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Syros Pharmaceuticals|SYRS - Company Aggregate Debts|Debt to Book Value Syros Pharmaceuticals, Inc|SYRS - Amount of Long-Term Liabilities|Company Short-Term Debts Syros Pharmaceuticals|Quick Ratio syros.com
- financial results and valuation multiples details:
SYRS - Net Income|Projected Future Earnings Syros Pharmaceuticals|SYRS - P/E Multiple|Future Price to Earnings Syros|SYRS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Syros Pharmaceuticals, Inc|SYRS - Operating income before deduction of amortization|Earnings per share for the last twelve months Syros Pharmaceuticals|SYRS - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months syros.com|SYRS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Syros Pharmaceuticals
- total revenue and sales volume data:
Fundamental company analysis:Syros Pharmaceuticals, Inc. (SYRS)
High binary risks for Syros Pharmaceuticals (SYRS) due to its dependence on a single leukemia drug make the valuation critically dependent on future cash flows. By analyzing the projected market cap-to-revenue ratio, an investor compares the current market price of the business with expected sales volume, allowing for a mathematical assessment of whether the asset is overvalued or undervalued and determining capital resilience during periods of volatility.
Competing companies
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Forward Price to Sales QGEN|IONS - Price-to-Projected Revenue Ratio|Repligen Inc. (RGEN) - Forward Price-to-Revenue Multiple|RNA: Forward P/S Multiple|crisprtx.com (CRSP) - Forward P/S Multiple|WGS (GeneDx) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Ultragenyx Pharmaceutical Inc. (RARE)|Forward P/S Multiple BEAM|SRPT - Market Cap to Future Revenue Ratio|Twist Bioscience - Forward Price-to-Revenue Multiple|Forward P/S Multiple 10xgenomics.com TXG|NTLA: Forward Price-to-Revenue Multiple|Stoke Therapeutics Inc - Price to Expected Revenue Ratio|BLFS: Forward P/S Multiple|WVE - Market Cap to Expected Sales Ratio|MAZE (Maze Therapeutics Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple sionnatx.com (SION)|Forward P/S Multiple PRME|Forward P/S Multiple Taysha Gene Therapies Inc (TSHA)|Price-to-Projected Revenue Ratio uniQure Corp QURE|MeiraGTx Corp - Price-to-Projected Revenue Ratio|RGNX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio solidbio.com SLDB|Ocugen (OCGN) - Price-to-Projected Revenue Ratio|PACB - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BNTC|Market Cap to Future Revenue Ratio Design Corp DSGN|Price-to-Projected Revenue Ratio Rocket Pharmaceuticals (RCKT)|FDMT (4dmoleculartherapeutics.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Lexeo Therapeutics, Inc. LXEO|Market Cap to Expected Sales Ratio Korro Bio Inc. (KRRO)|Editas - Forward P/S Multiple|SLN (Silence Therapeutics Corp) - Market Cap to Projected Revenue|proqr.com (PRQR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CDXS|SGMO (Sangamo Therapeutics, Inc.) - Forward P/S Multiple|Forward P/S Multiple Nautilus Biotechnology Inc|Price-to-Projected Revenue Ratio Metagenomi, Inc (MGX)|Market Cap to Expected Sales Ratio Precision BioSciences Inc.|Generation Bio - Forward Price-to-Revenue Multiple|boundlessbio.com (BOLD) - Market Cap to Future Revenue Ratio|XCUR - Price-to-Projected Revenue Ratio|Forward Price to Sales IMNN (Imunon, Inc.)|phiopharma.com (PHIO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Mustang Bio (MBIO)|Price-to-Projected Revenue Ratio TransCode Therapeutics Inc.|Bionano (BNGO) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple APDN (Applied DNA Sciences, Inc.)|BLUE (bluebird bio Inc.) - Forward Price to Sales|Price-to-Projected Revenue Ratio ImmunoPrecise Antibodies Ltd. IPA|OMGA (Omega Therapeutics Corp) - Future Price to Revenue|Singular Genomics Systems - Forward P/S Multiple|Forward Price to Sales RGLS (regulusrx.com)|TBIO: Forward P/S Multiple|TRACON Pharmaceuticals Inc. (TCON) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Unity Bio
